跳至主要内容
临床试验/NCT06392607
NCT06392607尚未招募不适用

Euclid Phoenix Lens Design Trial Part 2

Euclid Systems Corporation10 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年5月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
50
试验地点
10
主要终点
Lens wettability

研究概览

简要总结

Lens wettability and subjective comfort of Euclid orthokeratology lenses with and without an enhanced coating will be compared in 50 children. Axial elongation will be monitored in pediatric patients who qualify and consent.

详细描述

The primary objective of this trial is to provide an assessment of the lens wettability and patient comfort with an enhanced surface treatment for the Emerald Lens design when used by practitioners with moderate experience with fitting Euclid orthokeratology lenses.

The hypothesis to be tested is that the proportion of participants with a lens wettability score of > 3 (on a 5 point scale) with the enhanced surface treatment will be greater than that of the current lens surface, using a 1 to 5 scale

The primary outcome variable is lens wettability as measured on eye using a 1 to 5 scale

This clinical investigation will be a prospective, randomized, double-masked two-arm non-crossover trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
6 Years 至 35 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Be of legal age or, if under legal age have written consent of their parent or guardian to participate.
  • Sign written Informed Consent (and the California Bill of Rights, if applicable).
  • Ages 6-35 (inclusive) and able to understand and assent to participation
  • Current wearers of Euclid Emerald (Oprifocon A) Orthokeratology lenses, which at initiation of fitting, had
  • Need of optical correction for myopia, from -1.00 to -5.00 Diopters (D).
  • Refractive astigmatism of less than -1.50 D.
  • Have a minimum Best Spectacle Corrected Visual Acuity (BSCVA) of 20/40 or better in each eye.
  • Have acceptable or optimal fit with study lenses (once fitting has been completed) and be willing to wear these lenses as directed for the duration of the study.
  • On examination, have ocular findings considered to be within normal limits, including:
  • No evidence of active infection involving the conjunctiva, lids or adnexa.
  • No evidence of structural abnormalities of the lid, conjunctiva or adnexal tissue considered significant by the investigator to include minimum levels (Grade 2 or less) of tarsal-conjunctival abnormalities
  • Clear corneas with no evidence of edema, staining, opacities, corneal neovascularization greater than a trace amount (i.e. All vessels extending less than 1.5 mm from the limbus); all as observed on slit lamp examination.
  • No iritis.
  • No herpes keratitis (recurrent or otherwise) or other active ocular disease that would contraindicate lens wear or lessen attainability of VA sought in this study (20/40 or better).
  • No evidence of dry eye or meibomian gland dysfunction
  • Normal binocularity (no amblyopia or strabismus, and no anisometropia of greater than 2.00D)
  • Be willing and able to follow instructions and attend the schedule of follow-up visits.

排除标准

  • Does not meet the any of the above inclusion criteria
  • Not able or willing to provide informed consent and assent
  • Requires concurrent ocular medication
  • Eye injury or surgery within twelve weeks immediately prior to enrollment
  • Pre-existing ocular condition that would preclude contact lens fitting
  • Currently enrolled in an ophthalmic clinical trial
  • Pregnant or lactating or expect to become pregnant during the trial
  • Evidence of systemic or ocular abnormality, infection or disease likely to affect successful wear of contact lenses or use of their accessory solutions.
  • Allergy or sensitivity to any product used in this trial
  • Any systemic disease including autoimmune disease, immunocompromising diseases, connective tissue disease, clinically significant atopic diseases, insulin dependent diabetes, use of medications including corticosteroids and antimetabolites that may affect the eye or be exaggerated by contact lenses.
  • Strabismus/amblyopia
  • Habitual uncorrected anisometropia ≥ 2.00D
  • Subjects who have undergone corneal refractive surgery
  • Subjects with severe corneal irregularity contraindicating lens wear
  • Inability to wear contact lenses, or an unacceptable contact lens fit
  • Poor or unacceptable fit with any study lens
  • Employees, staff or family members of personnel at the site

结局指标

主要结局

Lens wettability

时间窗: 12 months

Lens wettability as measured on eye using a 1 to 5 scale

次要结局

  • Patient comfort ratings(12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验